|
505 Vioxx
withdrawn because of cardiovascular concerns Merck Sharp & Dohme has announced the immediate voluntary withdrawal of Vioxx (rofecoxib). The decision is a result of concerns raised in the APPROVe (adenomatous polyp prevention in Vioxx) study, which found an increased risk of heart attack and stroke after 18 months of treatment
...more
505 PCTs
too slow to commission new pharmacy services Provision of
new primary care services to patients is likely to be hindered by the
fact that many primary care trusts have been slow to grasp their new
strategic responsibilities, according to Howard Stoate MP, chairman of
the All Party Parliamentary Group on Primary Care and Public Health ...more
505 Put
patients in driving seat Patient choice in health care means
creating services with patients in the driving seat. This was the consensus
of a meeting organised on behalf of leading organisations representing
pharmacy held at the Conservative Party conference this week ...more
505 GPs
get new powers to commission services direct GP practices
will be able to commission services under new powers to be implemented
in April 2005 ...more
506 Evidence
of harm from antioxidant supplements Antioxidant supplements
are not effective in protecting against gastrointestinal cancers, a review
of trial data has revealed. What is more, the analysis showed that some
combinations of supplements may slightly increase cancer risk. Only selenium
was shown to be associated with risk reduction ...more
506 Diabetes
affects 1.8 million people in UK There are now 1.8 million
people with diabetes in the UK, according to new statistics released
by Diabetes UK ...more
506 Follow
up Muslim patients during Ramadan During Ramadan, Muslim patients
often unilaterally change the intake time and dosage of drugs without
taking medical advice, a recent review has found ...more
506 EHC
prescribing falls Prescribing of emergency hormonal contraception
is falling as more women realise that there are simpler ways of obtaining
it than seeing their GPs ...more
506 Immunoglobulin
in MS Intravenous immunoglobulin cannot be recommended for
patients with secondary progressive multiple sclerosis, say researchers
...more
507 MHRA
meets its targets, but criticism continues All the targets
set for the time it takes the Medicines and Healthcare products Regulatory
Agency to make medicines licensing decisions were exceeded last year.
But questions continue to be asked about the quality of some of its decisions
...more
507 OFT
says Drug Tariff may impede competition Competition may be
impeded by the Drug Tariff, the Office of Fair Trading says ...more
507 Flu
vaccine manufacturing halted by MHRA Fluvirin influenza vaccine
will not be available this year ...more
507 Minimum
wage rise
...more
507 CD
ROM on risk The Welsh Centre for Postgraduate Pharmaceutical
Education has launched an interactive learning programme on risk management
...more
508 European
paediatric research incentives not enough, says ABPI Proposed
regulations intended to encourage the pharmaceutical industry to test
medicines specifically for use in children are too little and too late,
according to the Association of the British Pharmaceutical Industry ...more
508 Call for
pharmacist-only medicines category Increasing complexity and the potential risks of some new over-the-counter medicines calls for consideration of a new category of medicines, “pharmacist-only” medicines, conference participants heard this week
...more
508 Joint health
teaching planned for Aberdeen Joint learning between pharmacy
students at Aberdeen’s Robert Gordon University and medical
students at the University of Aberdeen is to be encouraged with money
from the Scottish Executive ...more
508 Drug delivery
image wins national competition “Visualising drug delivery”, by David McCarthy, was the winning image in the “Concepts” category of this year’s Novartis/Daily Telegraph Visions of Science photographic awards
...more
508 Industrial
achievement awards made at BPC John Padfield received the
AstraZeneca Industrial Achievement Award for his outstanding contribution
to pharmaceutical sciences and the pharmaceutical industry ...more
508 ABPI code
booklet A booklet to provide NHS executives and managers with
information about the Association of the British Pharmaceutical Industry
code of practice, which goes beyond minimum legal requirements and seeks
to ensure that the promotion of medicines is carried out in a responsible,
professional and ethical manner, has been published by the ABPI ...more
|
R&D news
509 Gel
formulations set to be potential new treatments Advances in
gel formulations look set to deliver effective treatments for a variety
of diseases ...more
509 Promise
of immunotherapy for patients with rheumatoid arthritis An
experimental monoclonal antibody has shown promise as a treatment for
rheumatoid arthritis ...more
509 Strontium
ranelate shows efficacy in elderly population A reduction
in vertebral and non-vertebral fractures in women aged 80 years and over
has been shown in a study testing the effects of strontium ranelate,
a novel anti-osteoporotic agent ...more
509 Vitamin
analogue fights cancer A compound derived from vitamin E reduces
the size of tumours in mice, say researchers ...more
509 Cottonseed
for prostate cancer Gossypol, a drug refined from cottonseed
oil, may boost the effectiveness of prostate cancer treatment ...more
|
The
Pharmaceutical Journal